Dianthus Therapeutics, Inc. /DE/ (DNTH) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2025-12-31..
Gross margin
Overview →Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 2.04M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2025-12-31 | (m) | $2.04M | (m) | (m) |
| 2025-09-30 | (m) | $3.08M | (m) | (m) |
| 2025-06-30 | (m) | $4.85M | (m) | (m) |
| 2025-03-31 | (m) | $6.52M | (m) | (m) |
| 2024-12-31 | (m) | $6.24M | (m) | (m) |
| 2024-09-30 | (m) | $5.37M | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $2.83M | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $6.42M | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $1.48M | (m) | (m) |
| 2020-09-30 | (m) | $0.00 | (m) | (m) |
| 2020-06-30 | (m) | $0.00 | (m) | (m) |
| 2020-03-31 | (m) | $0.00 | (m) | (m) |
| 2019-12-31 | (m) | $0.00 | (m) | (m) |
| 2019-09-30 | (m) | $0.00 | (m) | (m) |
| 2019-06-30 | (m) | $0.00 | (m) | (m) |
| 2019-03-31 | (m) | $0.00 | (m) | (m) |
| 2018-12-31 | (m) | $0.00 | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $0.00 | (m) | (m) |
| 2017-12-31 | (m) | $0.00 | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |